
Short answer: RAD-150 is sold as an upgraded RAD-140, but there is no evidence it is better. PubChem lists RAD-150 (TLB-150) as RAD-140 benzoate: RAD-140 with a benzoate group attached, a molecule that appears in a 2014 patent from Radius Health, the company that developed RAD-140. In that patent’s lab test it bound the androgen receptor about 65 times more weakly than RAD-140. RAD-140 has one small human trial; RAD-150 has never been studied in cells, animals or people.
RAD-140 vs RAD-150 compared
| RAD-140 (testolone) | RAD-150 (TLB-150) | |
|---|---|---|
| What it is | Nonsteroidal SARM, first described in 2011 (now vosilasarm) | Listed as a benzoate ester of RAD-140; product identity not confirmed by any lab analysis |
| Androgen-receptor binding (patent lab test) | IC50 2 nM | IC50 130 nM (about 65 times weaker) |
| Human studies | 1 (Phase 1, 22 women with breast cancer); a Phase 1/2 trial is recruiting | None |
| Half-life | About 45 h (measured in the Phase 1 trial) | Not measured |
| Muscle evidence | Animals only (rats, monkeys) | None |
| Testosterone suppression | Not measured in men; about two-thirds lower in monkeys | Not studied |
| Liver | AST up in 59%, ALT in 45% of trial patients; several liver injury case reports | Not studied |
| WADA | Banned at all times (S1.2, named) | Banned as a SARM (S1.2 class) |
Source: Sarmguide compound database; RAD-140: ClinicalTrials.gov NCT05573126: Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer (2026).
What is RAD-140?
RAD-140 (testolone, now named vosilasarm) is a nonsteroidal SARM first described in 2011. Its only published human trial was a Phase 1 study in 22 postmenopausal women with advanced breast cancer, which measured a half-life of about 45 hours and found frequent liver-enzyme rises: AST in 59%, ALT in 45%, serious rises in 23%. It has never been tested for muscle in people; in young male monkeys, 28 days raised body weight by more than 10% and cut testosterone by about two-thirds.
For more information about Testolone, read our in-depth RAD 140 review.
What is RAD-150?
RAD-150 is sold as a newer version of RAD-140. PubChem files the name under “TLB 150 benzoate” (CID 68547459), formula C27H20ClN5O3: RAD-140 with a benzoyl group on its hydroxyl group. The same molecule is Example 87 of US patent 8,629,167 from Radius Health, where it was made from RAD-140 and benzoyl chloride. Confusingly, a PubChem search for “RAD-150” also returns an unrelated chemical that shares the name, and we found no published lab analysis of what products sold as RAD-150 actually contain.
Adding an ester can change how a drug is absorbed and released, but whether the body turns RAD-150 back into RAD-140 has never been tested.

Research
We don’t know anything about RAD 150.
The sad truth is, there hasn’t been much research done on RAD 140 either, but RAD 150 is a complete mystery to us.
This poses an obvious problem; everything written about RAD 150 is not verifiable since it’s not backed by research.
ClinicalTrials.gov lists no trials for RAD-150 or TLB-150, and PubMed has no studies of it at all (checked 30 October 2026). The only data point is the binding value in the patent, which suggests a weaker, not stronger, androgen-receptor effect in a lab test.
Results
Users often describe RAD-150 as slightly stronger than RAD-140, but no study has measured either compound’s effect on muscle in people, so there is nothing to compare. Reports of “10–15 pounds in 6–8 weeks” are anecdotes, and without lab analysis it is not even clear what each product contained.
For examples of results that you can expect with Testolone, check out our list of RAD 140 before and after results.

Side effects
RAD-150 has no safety data and no published case report naming it. If the body converts it into RAD-140, which no one has tested, RAD-140’s harms would apply: liver-enzyme rises in its trial, case reports of cholestatic liver injury, and case reports of heart-muscle inflammation and heart failure. Users report hair shedding, aggression and suppression with both. The FDA warns that SARM products as a group have caused life-threatening reactions, including liver injury, and may increase the risk of heart attack and stroke.
Dosing
We do not give personal doses. The only human doses ever studied for RAD-140 were 50–150 mg/day in women with advanced breast cancer, far above what is sold to lifters; the maximum tolerated dose was 100 mg/day. No dose of RAD-150 has been studied at all. See the RAD-140 dosage guide for what the trial used.
Half-life
RAD-140’s half-life was about 45 hours in its Phase 1 trial (an earlier conference abstract gave a different figure; the published paper is the better source). RAD-150’s half-life has never been measured, so claims that it lasts longer are guesses.
Taste
People that have tried both RAD 140 and RAD 150 report the latter actually having better taste than the former.
That is an anecdote, and it does not matter much: most products are now capsules.
Legal status
Neither is approved anywhere. The FDA says products sold as SARMs are unapproved drugs, not supplements. UK Anti-Doping lists RAD-150 (TLB-150) among SARMs, and WADA’s S1.2 ban covers SARMs as a class, so both are banned in sport at all times. In Australia, SARMs are prescription-only and possession without a prescription is illegal. See are SARMs legal?

RAD-140 vs RAD-150: the verdict
RAD-140 is a poorly studied SARM with a clear liver signal; RAD-150 is an unstudied derivative of it. The only lab data point suggests RAD-150 binds the androgen receptor more weakly, and nothing shows it is stronger, longer-acting or safer. If you are weighing either, read the RAD-140 and RAD-150 fact sheets first, and compare them with other compounds in the compare tool.
Frequently asked questions
What is the difference between RAD-140 and RAD-150?
RAD-150 is an untested esterEvidence: Lab
RAD-150 is listed as RAD-140 benzoate, and in a patent lab test it bound the androgen receptor about 65 times more weakly. RAD-140 has one small human trial; RAD-150 has none.
Is RAD-150 stronger than RAD-140?
No evidence it isEvidence: Lab
No study has tested RAD-150 for any effect, and the only lab data point shows weaker androgen-receptor binding than RAD-140.
Is RAD-150 the same as TLB-150?
Same name, per PubChemEvidence: Limited
Sellers use both names, and PubChem files RAD-150 under TLB 150 benzoate. A search for "RAD-150" also returns an unrelated chemical that shares the name.
What is the half-life of RAD-150?
UnknownEvidence: Limited
It has never been measured; RAD-140's half-life was about 45 hours in its Phase 1 trial. Claims that RAD-150 lasts longer are guesses.
Does RAD-150 have fewer side effects than RAD-140?
No evidenceEvidence: Limited
RAD-150 has no safety data at all. If the body turns it into RAD-140, which has never been tested, RAD-140's liver and heart case reports would apply.
Is RAD-150 a steroid?
NoEvidence: Lab
Like RAD-140, it is a nonsteroidal molecule that acts on the androgen receptor. It is banned in sport as a SARM.
Is RAD-150 legal?
Not approved; banned in sportEvidence: Law
It is not approved anywhere, and the FDA says products sold as SARMs are unapproved drugs. UK Anti-Doping lists RAD-150 among SARMs, which WADA bans at all times.
Do you need PCT after RAD-150?
Unknown; never measuredEvidence: Animal
Its effect on hormones has never been measured. RAD-140, its parent compound, cut testosterone by about two-thirds in monkeys.
Sources
- A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer
- Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140
- PubChem: TLB 150 Benzoate (synonyms RAD150, RAD-150?), CID 68547459
- US Patent 8,629,167 B2: Selective androgen receptor modulators (Radius Health; granted 14 January 2014), Example 87 and Table 1
- RAD-140 Drug-Induced Liver Injury
- Acute Myocarditis From the Use of Selective Androgen Receptor Modulator (SARM) RAD-140 (Testolone)
- FDA: Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more (content current as of 2 December 2025)
- SARMs | UK Anti-Doping (supplement ingredient warning, updated 29 April 2026)
- WADA: The Prohibited List (2026 List, in force from 1 January 2026)